Key Highlights
- Loss per share was USD 1.29 against an estimate of a USD 0.83 loss.
- Net loss was USD 62.42 million, against USD 21.62 million a year earlier.
- General and administrative expenses were USD 34.3 million, against USD 4.7 million.
- Cash and marketable securities were USD 481.6 million at September 30.
MBX Biosciences (NASDAQ:MBX) reported a third quarter 2026 loss per share of USD 1.29, against an estimate of a USD 0.83 loss. Net loss was USD 62.42 million, compared with USD 21.62 million in the third quarter of 2025.
The loss from operations was USD 66.34 million, against USD 23.93 million a year earlier. The company reported the figures in its quarterly filing for the period ended September 30, 2026, and said it does not have any products approved for sale and has not generated any Revenue from product sales.
Operating Expenses
Research and development expenses were USD 32.05 million, compared with USD 19.27 million. General and administrative expenses were USD 34.3 million, compared with USD 4.7 million. Total operating expenses were USD 66.34 million, against USD 23.93 million.
The filing reports stock-based compensation within general and administrative expense of USD 25.49 million for the quarter, compared with USD 1.32 million, and total stock-based compensation of USD 27.55 million, compared with USD 2.25 million.
Nine-Month Results
For the nine months ended September 30, 2026, total operating expenses were USD 134.54 million, against USD 72.26 million. Research and Development expenses were USD 81.51 million, against USD 59.40 million, and general and administrative expenses were USD 53.03 million, against USD 12.86 million.
Interest and other income, net, which includes interest income and amortization of premiums and discounts on marketable securities, was USD 3.9 million for the quarter, compared with USD 2.3 million. Nine-month net loss was USD 123.03 million, compared with USD 64.91 million, and nine-month interest and other income, net, was USD 11.51 million, against USD 7.35 million. The nine-month loss from operations was USD 134.54 million, against USD 72.26 million. The filing also shows an unrealized loss on marketable securities of USD 0.74 million for the quarter, against an unrealized gain of USD 0.14 million.
Liquidity and Offerings
As of September 30, 2026, the company had an accumulated Deficit of USD 347.5 million and cash, cash equivalents and marketable securities of USD 481.6 million. Based on its current operating plan, management believes existing cash and cash equivalents and marketable securities are sufficient to fund its obligations for at least 12 months from the date of issuance of the financial statements.
In September 2025, the company completed an underwritten public offering of 11,108,055 shares of its common stock, which generated approximately USD 199.9 million in aggregate gross proceeds. The filing also describes an operating Lease agreement for its principal executive office in Carmel, Indiana, entered into in April 2022 and amended in May 2025.
MBX Biosciences Q3 2026 Earnings: Key Takeaways
MBX Biosciences reported a third quarter 2026 loss per share of USD 1.29 and a net loss of USD 62.42 million. General and administrative expenses were USD 34.3 million, and cash, cash equivalents and marketable securities were USD 481.6 million.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...